drugset
drugset / Trial / NCT05712200

Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)

NCT05712200 ↗

Phase 3 Recruiting 2500 enrolled Anthos Therapeutics, Inc. Novartis Pharmaceuticals · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

A study to evaluate the effect of abelacimab relative to placebo on the rate of ischemic stroke or systemic embolism (SE) in patients with Atrial Fibrillation (AF) who have been deemed by their responsible physicians or by their own decision to be unsuitable for oral anticoagulation therapy.

Timeline

Start
2022-12-27
Primary completion
2027-12-30
Completion
2027-12-30

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Abelacimab Monoclonal antibody 150 mg Subcutaneous

Indications

atrial fibrillation